scholarly journals Insights into the SARS-CoV-2 Diagnosis in India: Present Status and Future Prospects

Author(s):  
Laxmipreeya Behera ◽  
Jyoti Prakash Sahoo ◽  
Sushree Suparna Mahapatra ◽  
Jannila Praveena ◽  
Trupti Dash ◽  
...  

COVID-19, the infectious pandemic disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This deadly disease was unknown before its catastrophic outbreak of the infection in Wuhan city of China, in December 2019. The pandemic situation has increased the demand of rapid enhancement of the in-vitro diagnostic assays which would enable the mass screening and testing. Several molecular and serological diagnostics assays such as direct viral antigen tests, nucleic acid amplification tests and serological tests were developed. Nucleic acid tests such as RT-PCR. TrueNAT, Feluda Test, loop-mediated isothermal amplification (LAMP) etc. detect the presence of RNA virus in the nasal or throat swab or from saliva. Antigen tests detect the presence of a virus as the antigen, which is a surface protein. Antibody tests such as enzyme-linked immunosorbent assays (ELISA), lateral flow assays (LFA), chemiluminescence assays (CLIA) etc. detect the presence of antibodies generated against SARS-CoV-2 in the blood samples.

Author(s):  
Nensi Raytthatha ◽  
Isha Shah ◽  
Jigar Vyas ◽  
Umesh Upadhyay

Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) is a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute respiratory disease, named ‘coronavirus disease 2019’ (COVID-19), which threatens human health and public safety. The disease caused by SARS‐CoV‐2, coronavirus disease 2019 (COVID‐19), presents flu‐like symptoms which can become serious in high‐risk individuals. During the early phase of the coronavirus (COVID-19) pandemic, design, development, validation, verification and implementation of diagnostic tests were actively conveyed by a large number of diagnostic test manufacturers. In this Review, we give an outline of the crucial role of diagnostic tests during the first world-wide indication of COVID-19. The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) and its associated coronavirus (COVID-19) pandemic has demanded rapid up scaling of in-vitro diagnostic assays to enable mass screening and testing of high-risk groups. To encounter the exponential demand in testing, there has been an expedite development of both molecular and serological assays across a superfluity of manifestos. The adjacent review discusses the current information on these modalities, including nucleic acid amplification tests, direct viral antigen tests. In the analytic stage, real-time reverse transcription-PCR (RT-PCR) assays remain the molecular test of choice for the etiologic diagnosis of SARS-CoV-2.


2020 ◽  
Vol 2 (1) ◽  
pp. 32
Author(s):  
Mariana Wahjudi

Abstract—The governance of COVID-19 cases in Indonesia is carried out in accordance with the WHO directions. Serological tests, often mentioned as rapid antibody tests, are used for mass screening testing while the polymerase-chain-reaction (PCR)-based tests are performed for routine confirmation of COVID-19 infection cases. PCR test is one of nucleic acid amplification tests (NAAT) for detection of viral RNA. The management of the COVID-19 detection caused controversies at the beginning of pandemic period. It seems that the controversies occurred due to misperception regarding the tests, as well as misunderstanding caused by differences in individual immune responses, viral dynamics in human bodies and clinical outcomes. In response to community opinion controversies, this paper discuss the following topics, i.e. a glimpse about COVID-19, the characteristics of SARS-CoV-2, viral dynamics in human body, the dynamics of human immune response to SARS-CoV-2, basic explanation about COVID-19 and SARS-CoV-2 testing, and the last part explained the occurred controversies. Keywords: Indonesia, polymerase chain reaction, rapid test, SARS-CoV-2, serology Abstrak— Penetapan pelaksanaan deteksi kasus COVID-19 di Indonesia dilaksanakan sesuai arahan WHO. Uji serologis atau rapid test antibodi digunakan untuk test atau skrining massal sedangkan untuk uji berbasis polymerase-chain-reaction (PCR) digunakan untuk konfirmasi rutin kasus infeksi COVID-19. Uji molekuler secara PCR merupakan salah satu metode nucleic acid amplification tests (NAAT), untuk mendeteksi RNA virus. Penatalaksanaan deteksi Coronavirus disease 2019 (COVID-19) ini di awal masa pandemik menimbulkan berbagai kontroversi di masyarakat. Kontroversi terjadi terutama karena pemahaman yang berbeda dari masyarakat mengenai prinsip pengujian dan adanya salah pengertian akibat adanya perbedaan respon immun antar individu, dinamika virus COVID-19 dalam tubuh orang terinfeksi, dan luaran klinis pasien. Menanggapi kontroversi pendapat di masyarakat maka pada tulisan ini dibahas tentang sekilas COVID-19, karakteristik SARS-CoV-2, dinamika virus dan pembentukan antibodi dalam tubuh manusia, penjelasan prinsip pengujian COVID-19 dan SAR-CoV-2 serta ulasan tentang kontroversi yang terjadi. Kata kunci: Indonesia, polymerase chain reaction, rapid test, SARS-CoV-2, serology


Pharmaceutics ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 888
Author(s):  
Hiro Uemachi ◽  
Yuuya Kasahara ◽  
Keisuke Tanaka ◽  
Takumi Okuda ◽  
Yoshihiro Yoneda ◽  
...  

Nucleic acid aptamers have attracted considerable attention as next-generation pharmaceutical agents and delivery vehicles for small molecule drugs and therapeutic oligonucleotides. Chemical modification is an effective approach for improving the functionality of aptamers. However, the process of selecting appropriately modified aptamers is laborious because of many possible modification patterns. Here, we describe a hybrid-type systematic evolution of ligands by exponential enrichment (SELEX) approach for the generation of the artificial nucleic acid aptamers effective against human TROP2, a cell surface protein identified by drug discovery as a promising target for cancer therapy. Capillary electrophoresis SELEX was used for the pre-screening of multiple modified nucleic acid libraries and enrichment of TROP2 binding aptamers in the first step, followed by functional screening using cell-SELEX in the second step for the generation of cell-internalizing aptamers. One representative aptamer, Tac-B1, had a nanomolar-level affinity to human TROP2 and exhibited elevated capacity for internalization by cells. Because of the growing interest in the application of aptamers for drug delivery, our hybrid selection approach has great potential for the generation of functional artificial nucleic acid aptamers with ideal modification patterns in vitro.


2021 ◽  
Author(s):  
Nigel A Makoah ◽  
Thomas Tipih ◽  
Matefo M Litabe ◽  
Mareza Brink ◽  
Joseph B Sempa ◽  
...  

Aim: The aim of this study was to investigate the utility of serological tests for the diagnosis of COVID-19 during the first week of symptom onset in patients confirmed with the real-time RT-PCR. Materials & methods: A systematic review and meta-analysis of 58 publications were performed using data obtained from Academic Search Ultimate, Africa-wide, Scopus, Web of Science and MEDLINE. Results: We found that the highest pooled sensitivities were obtained with ELISA IgM-IgG and chemiluminescence immunoassay IgM tests. Conclusion: Serological tests have low sensitivity within the first week of symptom onset and cannot replace nucleic acid amplification tests. However, serological assays can be used to support nucleic acid amplification tests.


2020 ◽  
Vol 41 (10) ◽  
pp. 1148-1153
Author(s):  
Andrew M. Skinner ◽  
Brian Yu ◽  
Adam Cheknis ◽  
Susan M. Pacheco ◽  
Dale N. Gerding ◽  
...  

AbstractBackground:Most clinical microbiology laboratories have replaced toxin immunoassay (EIA) alone with multistep testing (MST) protocols or nucleic acid amplification testing (NAAT) alone for the detection of C. difficile.Objective:Study the effect of changing testing strategies on C. difficile detection and strain diversity.Design:Retrospective study.Setting:A Veterans’ Affairs hospital.Methods:Initially, toxin EIA testing was replaced by an MST approach utilizing a glutamate dehydrogenase (GDH) and toxin EIA followed by tcdB NAAT for discordant results. After 18 months, MST was replaced by a NAAT-only strategy. Available patient stool specimens were cultured for C. difficile. Restriction endonuclease analysis (REA) strain typing and quantitative in vitro toxin testing were performed on recovered isolates.Results:Before MST (toxin EIA), 79 of 708 specimens (11%) were positive, and after MST (MST-A), 121 of 517 specimens (23%) were positive (P < .0001). Prior to NAAT-only testing (MST-B), 80 of the 490 specimens (16%) were positive by MST, and after NAAT-only testing was implemented, 67 of the 368 specimens (18%) were positive (P = nonsignificant). After replacing toxin EIA testing, REA strain group diversity increased (8, 13, 13, and 10 REA groups in the toxin EIA, MST-A, MST-B, and NAAT-only periods, respectively) and in vitro toxin concentration decreased. The average log10 toxin concentration of the isolates were 2.08, 1.88, 1.20 and 1.55 ng/mL for the same periods, respectively.Conclusions:MST and NAAT had similar detection rates for C. difficile. Compared to toxin testing alone, they detected increased diversity of C. difficile strains, many of which were low toxin producing.


Sign in / Sign up

Export Citation Format

Share Document